Overview

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients Without Prior Antiviral Therapy

Status:
Recruiting

Trial end date:
2021-10-12

Target enrollment:

Participant gender:

Summary

To evaluate the safety, tolerability of single dose lipovirtide injection in HIV-infected individuals without prior antiviral treatment, and to investigate the pharmacokinetic characteristics of infected patients.

Phase:

Phase 1

Details

Lead Sponsor:

Shanxi Kangbao Biological Product Co., Ltd.

Collaborator:

Chinese Academy of Medical Sciences